GGrantIndex
Sort

23,748 grants matching melanoma

MECHANISMS OF IMMUNOSUPPRESSION BY ONE DOSE OF ETHANOL

$186,643
Louisiana State Univ Hsc Shreveport · R01 · FY2003 · AA

TOMOGRAPHIC/SPECTRAL IMAGING OF FGF-MED ANGIOGENESIS

$186,627
University Of Pittsburgh At Pittsburgh · R01 · FY2000 · CA

Identification of small molecule inhibitors of USP15

$186,552
Anton Simeonov · National Center For Advancing Translational Sciences · ZIA · FY2020 · TR

GENETIC INSTABILITY AND THE CELL CYCLE

$186,544
University Of Washington · P01 · FY2000 · CA

Programmable 'all-in-one' RNA as a molecular scaffold for targeted combinatorial innate immune activation

$186,537
Connie Wu · University Of Michigan At Ann Arbor · R21 · FY2025 · EB

Melanoma suppressing functions of carcinoma oncogene FOXQ1

$186,506
Mikhail Nikiforov · Roswell Park Cancer Institute Corp · R21 · FY2016 · CA

EASTERN COOPERATIVE ONCOLOGY GROUP

$186,449
University Of Pretoria · U10 · FY2000 · CA

Effects of a Novel Phospho-STAT2 inhibitor for Treatment of Stage IV Melanoma

$186,434
Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · P50 · FY2011 · CA

The Impact of Innate Neuronal Immunity on Neurotropic Arbovirus Pathogenesis

$186,390
David J Miller · University Of Michigan At Ann Arbor · R21 · FY2008 · AI

CELLULAR PROTEIN MATURATION AND DEGRADATION

$186,350
University Of Massachusetts Amherst · R01 · FY2000 · CA

SBIR TOPIC 229 MELANOMA PHARMACODYNAMIC ASSAY FOR TARGETED THERAPY

$186,321
Siconolfi Lisa · · N01 · FY2007 · CA

Core 3: Rexinoid Screening and Animal Core

$186,229
Mohammad Athar · University Of Alabama At Birmingham · P01 · FY2021 · CA

Detection of Melanoma by Mesoscopic Spectral Imaging

$186,146
University Of Pittsburgh At Pittsburgh · R21 · FY2003 · CA

MODULATION OF NF-kB ACTIVATION BY A NOVEL MITOCHONDRIAL E3 UBIQUITIN LIGASE

$186,121
Claudio A.p. Joazeiro · Scripps Research Institute, The · R01 · FY2012 · GM

MODULATION OF NF-kB ACTIVATION BY A NOVEL MITOCHONDRIAL E3 UBIQUITIN LIGASE

$186,121
Claudio A.p. Joazeiro · Scripps Research Institute, The · R01 · FY2011 · GM

Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma

$185,992
Brendan D Curti · Providence Portland Medical Center · R21 · FY2016 · CA

Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming

$185,977
Samuel G Katz · Yale University · R21 · FY2024 · CA

Redox Mechanism Process of Nos2 and COX2 in Stroma tumor interaction

$185,930
David Wink · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

VPF/VEGF IN NORMAL AND NEOPLASTIC SKIN ANGIOGENESIS

$185,896
Massachusetts General Hospital · R01 · FY2000 · CA

PG545 synergizes with PARP inhibitors in ovarian cancer to disrupt DNA repair through modulation of DEK-RAD51 axis

$185,831
Viji Shridhar · Mayo Clinic Rochester · R21 · FY2022 · CA

Discovery of PD-1/PDL-1 inhibitors from marine microbial natural products

$185,808
William Fenical · University Of California, San Diego · R01 · FY2023 · CA

Discovery of PD-1/PDL-1 inhibitors from marine microbial natural products

$185,807
William Fenical · University Of California, San Diego · R01 · FY2022 · CA

Rationally improving T cell-mediated immunotherapy using Sleeping Beauty mutagenesis

$185,760
Laura Marie Rogers · Mayo Clinic Rochester · K22 · FY2021 · CA

Rationally improving T cell-mediated immunotherapy using Sleeping Beauty mutagenesis

$185,760
Laura Marie Rogers · Mayo Clinic Rochester · K22 · FY2020 · CA

Rationally improving T cell-mediated immunotherapy using Sleeping Beauty mutagenesis

$185,760
Laura Marie Rogers · Mayo Clinic Rochester · K22 · FY2019 · CA